Cure Sickle Cell

治愈镰状细胞

• 批准号: 10270068
• 负责人: MARY EAPEN
• 金额: $ 987.22万
• 依托单位: MEDICAL COLLEGE OF WISCONSIN
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-28 至 2023-09-27
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10270068
• 关键词: Advocate; Biological Products; Caregivers; Collaborations; Communities; Family member; Government Agencies; Individual; National Heart, Lung, and Blood Institute; Patients; Research Personnel; Sickle Cell; Sickle Cell Anemia; Technology; Work; gene therapy; improved; innovation; public-private partnership

The Cure Sickle Cell (CureSC) Initiative was created in 2017 by the National Heart, Lung, and Blood Institute (NIH/NHLBI) to: • Actively engage the sickle cell disease community of patients, family members, caregivers and advocates to work together on a path to the cure • Utilize the emergence of safe reliable genetic therapies that broadens opportunities to improve the lives of individuals with sickle cell disease • Use public-private partnership and collaboration among government agencies, biopharmaceutical companies and researchers to result in more rapid advancement of new and innovative treatments and technologies

Cure Cure镰状细胞（CURESC）倡议是由国家心脏，肺和血液研究所（NIH/NHLBI）于2017年创建的： •积极参与患者，家庭成员，看护人和拥护者的镰状细胞病社区，以在治愈方向上共同努力 •利用安全可靠的基因疗法的出现，可以扩大机会改善镰状细胞病的生活的机会 •使用政府机构，生物制药公司和研究人员之间的公私合作伙伴关系和合作，从而更快地进步了新的和创新的治疗方法和技术